Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease Genzyme, 10 Apr 2010 Accessed on 6 Dec 2011 from http://www.businesswire.com/news/genzyme/20100414005228/en. CommentRecommendBookmarkWatch